Tazemetostat is a selective methyltransferase inhibitor, specifically targeting EZH2, used in the treatment of epithelioid sarcoma and follicular lymphoma. As an epigenetic modulator, it works by inhibiting… Read more
Tazemetostat is a selective methyltransferase inhibitor, specifically targeting EZH2, used in the treatment of epithelioid sarcoma and follicular lymphoma. As an epigenetic modulator, it works by inhibiting histone methylation, which helps regulate gene expression in certain cancer cells. This category provides essential tools for rigorous pharmaceutical analysis, including high-quality reference standards and stable isotope labelled compounds such as Tazemetostat-d8. These materials are critical for laboratories conducting impurity profiling, method validation, and quantitative bioanalysis. By serving as internal standards in mass spectrometry and other analytical techniques, these labelled compounds allow researchers to achieve precise measurement of drug concentrations in biological matrices. Accessing these well-characterized reference materials supports accurate quality control processes and ensures the reliability of data generated during pharmacokinetic studies and regulatory submissions for this important therapeutic agent.